Inclusion Criteria:

- Histologically confirmed adenocarcinoma of the prostate

- Metastatic prostate cancer deemed to be unresponsive or refractory to hormone therapy
(after discontinuation of anti-androgen therapy)

- Detectable metastases by bone scan, and/or CT scan, and/or MRI, and/or CXR

- ECOG performance status 0-1

Exclusion Criteria:

- Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer

- History of deep vein thrombosis or pulmonary embolus

- Patients taking anticoagulants (such as coumadin or Heparin). The use of aspirin
while on study is acceptable.

- History of a bleeding disorder or recent clinically significant bleeding

- Seropositive for HIV

- History of Hepatitis B, Hepatitis C, or chronic liver disease

- Prior gene therapy or immunotherapy

- Prior chemotherapy for prostate cancer

- Radiation therapy within 4 weeks of the first treatment.

- History of myocardial infarction within 6 months of the first treatment

- History of cerebrovascular accident

- History of previous malignancy, except for the following: adequately treated basal
cell or squamous cell skin cancer, superficial bladder cancer, adequately treated
Stage I or II cancer currently in complete remission, or any other cancer that has
been in complete remission for at least 5 years

- Evidence of active prostatitis

- Known hypersensitivity to docetaxel or to other drugs formulated with polysorbate 80